SKYRIZI 360 MG / 2.4 ML
RISANKIZUMAB : 360 MG / 2.4 ML · DIN 02532093 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is SKYRIZI?
SKYRIZI 360 MG / 2.4 ML contains RISANKIZUMAB : 360 MG / 2.4 ML. It is listed in the Health Canada Drug Product Database under DIN 02532093, held by ABBVIE CORPORATION, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 14-Mar-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SKYRIZI used for?
Skyrizi is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, adult patients with active psoriatic arthritis, adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies, and adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02532093 |
|---|---|
| Brand name | SKYRIZI |
| Generic / active ingredient | RISANKIZUMAB : 360 MG / 2.4 ML |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 360 MG / 2.4 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L04AC18 RIZANKIZUMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Mar-2023 |
How is it stored and handled?
Once diluted, the solution can be stored (protected from sun light) at room temperature between 15 to 30°C (59 to 86°F) for administration within 8 hours or, refrigerated immediately for up to 20 hours between 2 and 8°C (36 and 46°F) for later administration. Do not freeze.
How is it supplied?
Skyrizi (risankizumab injection) 150 mg/1 mL (150 mg/mL) is available in cartons containing one pre-filled pen or one pre-filled syringe. Skyrizi (risankizumab injection) 180 mg/1.2 mL (150 mg/mL) is available in cartons containing one pre-filled cartridge with one on-body injector. Skyrizi (risankizumab injection) 360 mg/2.4 mL (150 mg/mL) is available in cartons containing one pre-filled cartridge with one on-body injector. Skyrizi (risankizumab injection) 90 mg/1 mL (90 mg/mL) is available in cartons containing 4 pre-filled syringes. Skyrizi (risankizumab for injection) 600 mg/10 mL (60 mg/mL) is available in cartons containing one vial.
What can be used instead?
Other Canadian products sharing ATC code L04AC18 RIZANKIZUMAB. 5 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SKYRIZI | 150 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02519283 |
| SKYRIZI | 150 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02519291 |
| SKYRIZI | 180 MG / 1.2 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02552507 |
| SKYRIZI | 60 MG | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02532107 |
| SKYRIZI | 75 MG / 0.83 ML | SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 02487454 |
| SKYRIZI | 90 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | APPROVED | DIN 02546922 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.